Skip to main content

Table 1 General characteristics of all T2DM subjects according to follow-up

From: Vitamin D supplementation as an adjuvant therapy for patients with T2DM: an 18-month prospective interventional study

 

Baseline

6 Months

12 Months

18 Months

P value

N

92

    

M/F

34/58

    

DMT2 Duration (years)

7.2 ± 5.9

    

Insulin (N%)

18 (19.6)

    

Sulfonylurea (N%)

68 (73.9)

    

Statins (N%)

44 (47.8)

    

Diet (N%)

6 (6.5)

    

Age (years)

53.9 ± 10.2

    

Systolic BP (mmHg)

126.0 ± 14.1

125.3 ± 17.2

128.4 ± 14.4

126.1 ± 8.1

0.46

Diastolic BP (mmHg)

79.6 ± 7.3

79.0 ± 10.1

79.6 ± 9.5

77.2 ± 6.2

0.27

BMI (kg/m2)

32.5 ± 5.0

32.6 ± 4.9

32.8 ± 4.9

33.2 ± 5.2

0.12

Glucose (mmol/l)

10.7 ± 3.8

11.0 ± 4.3

11.7 ± 4.1

10.9 ± 4.4

0.21

T. Cholesterol (mmol/l)

5.4 ± 0.21

5.2 ± 0.25

4.9 ± 0.22*

4.8 ± 0.28*

<0.001

Triglycerides (mmol/l)

1.9 ± 0.33

2.0 ± 0.32

1.9 ± 0.26

1.9 ± 0.34

0.15

HDL-Chol (mmol/l)

1.0 ± 0.35

1.1 ± 0.26

1.12 ± 0.27

1.2 ± 0.37

0.38

LDL-Chol (mmol/l)

4.3 ± 0.93

4.0 ± 0.85

3.7 ± 1.1*

3.7 ± 1.0*

0.004

Corr. Calcium (mmol/l)

2.3 ± 0.23

2.4 ± 0.17

2.5 ± 0.22

2.56 ± 0.14*

0.003

Albumin (g/L)

43.5 ± 6.5

40.3 ± 6.6

40.0 ± 4.0*

39.5 ± 4.7*

<0.001

Insulin (IU/ml)

14.0 ± 2.0

18.9 ± 2.3

27.0 ± 1.8*

24.5 ± 2.1*

<0.001

PTH (pmole/l)

1.3 ± 0.39

0.96 ± 0.24

0.91 ± 0.22*

0.92 ± 0.23*

0.02

HOMA-IR

6.2 ± 1.0

8.0 ± 1.0

11.9 ± 1.0*

11.4 ± 1.4*

<0.001

HOMA β-cell function

52.1 ± 9.0

72.5 ± 15.3

82.7 ± 9.5*

96.5 ± 15.3*

0.002

25-(OH) D (nmol/l)

32.2 ± 1.5

57.7 ± 1.4*

48.1 ± 1.4*#

54.7 ± 1.5*

<0.001

Magnesium (mmol/l)

0.69 ± 0.11

0.67 ± 0.08

0.66 ± 0.05

0.70 ± 0.15

0.65

Phosphorus (mmol/l)

1.17 ± 0.23

1.17 ± 0.23

1.13 ± 0.22

1.11 ± 0.23

0.16

  1. Note: Data presented as mean ± SD; * denotes significance compared to baseline; # denotes significance compared to 6 months; P-value significant at <0.05.